1. Home
  2. LGHL vs CDT Comparison

LGHL vs CDT Comparison

Compare LGHL & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGHL

Lion Group Holding Ltd.

HOLD

Current Price

$2.19

Market Cap

2.2M

Sector

Finance

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$1.53

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGHL
CDT
Founded
2015
2019
Country
Singapore
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LGHL
CDT
Price
$2.19
$1.53
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
144.8K
115.9K
Earning Date
04-30-2024
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.20
$1.24
52 Week High
$126.23
$2,198.40

Technical Indicators

Market Signals
Indicator
LGHL
CDT
Relative Strength Index (RSI) 40.67 43.59
Support Level $2.32 $1.36
Resistance Level $2.39 $1.55
Average True Range (ATR) 0.25 0.10
MACD -0.17 0.02
Stochastic Oscillator 3.97 51.40

Price Performance

Historical Comparison
LGHL
CDT

About LGHL Lion Group Holding Ltd.

Lion Group Holding Ltd is an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, Hong Kong-based Over-The-Counter (OTC) stock options trading business, and futures and securities brokerage services. It provides these services through its Lion Brokers Pro and a variety of other applications. The company generates a majority of its revenue from its CFD trading services business. Geographically, the firm's key revenue-generating market is Hong Kong.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: